UniProtKB/Swiss-Prot P10636 : Variant p.Pro618Leu
Microtubule-associated protein tau
Gene: MAPT
Feedback ?
Variant information
Variant position:
618
The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant:
LP/P [Disclaimer : Variants classification is intended for research purposes only, not for clinical and diagnostic use . The label disease variant is assigned according to literature reports on probable disease-association that can be based on theoretical reasons. This label must not be considered as a definitive proof for the pathogenic role of a variant. ]
The variants are classified into three categories: LP/P, LB/B and US.LP/P: likely pathogenic or pathogenic. LB/B: likely benign or benign. US: uncertain significance
Residue change:
From Proline (P) to Leucine (L) at position 618 (P618L, p.Pro618Leu).
Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties:
Similar physico-chemical property. Both residues are medium size and hydrophobic.
The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score:
-3
The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another: Lowest score: -4 (low probability of substitution).Highest score: 11 (high probability of substitution). More information can be found on the following page
Variant description:
In FTD; most common mutation; reduction in the ability to promote microtubule assembly; accelerates aggregation of tau into filaments.
Any additional useful information about the variant.
Other resources:
Links to websites of interest for the variant.
Sequence information
Variant position:
618
The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length:
758
The length of the canonical sequence.
Location on the sequence:
KLDLSNVQSKCGSKDNIKHV
P GGGSVQIVYKPVDLSKVTSK
The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation:
The multiple alignment of the region surrounding the variant against various orthologous sequences.
Human KLDLSNVQSKCGSKDNIKHVP GGGSVQIVYKPVDLSKVTSK
Gorilla KLDLSNVQSKCGSKDNIKHVP GGGSVQIVYKPVDLSKVTSK
Rhesus macaque KLDLSNVQSKCGSKDNIKHVP GGGSVQIVYKPVDLSKVTSK
Chimpanzee KLDLSNVQSKCGSKDNIKHVP GGGSVQIVYKPVDLSKVTSK
Mouse KLDLSNVQSKCGSKDNIKHVP GGGSVQIVYKPVDLSKVTSK
Rat KLDLSNVQSKCGSKDNIKHVP GGGSVHIVYKPVDLSKVTSK
Bovine KLDLSNVQSKCGSKDNIKHVP GGGSVQIVYKPVDLSKVTSK
Goat KLDLSNVQSKCGSKDNIKHVP GGGSVQIVYKPVDLSKVTSK
Sequence annotation in neighborhood:
The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:Type: the type of sequence feature. Positions: endpoints of the sequence feature. Description: contains additional information about the feature.
Type Positions Description
Chain
2 – 758
Microtubule-associated protein tau
Repeat
592 – 622
Tau/MAP 2
Region
561 – 685
Microtubule-binding domain
Site
607 – 607
Not glycated
Site
611 – 611
Not glycated
Site
615 – 615
Not glycated
Site
628 – 628
Not glycated
Site
634 – 634
Not glycated
Site
638 – 638
Not glycated
Modified residue
598 – 598
N6-acetyllysine; alternate
Modified residue
602 – 602
Phosphoserine; by PHK
Modified residue
607 – 607
N6-acetyllysine
Modified residue
610 – 610
Phosphoserine
Modified residue
615 – 615
N6-acetyllysine; alternate
Modified residue
622 – 622
Phosphoserine; by PHK
Modified residue
628 – 628
N6,N6-dimethyllysine; alternate
Modified residue
628 – 628
N6-acetyllysine; alternate
Modified residue
634 – 634
N6-acetyllysine; alternate
Modified residue
638 – 638
N6-acetyllysine; alternate
Glycosylation
598 – 598
N-linked (Glc) (glycation) lysine; in PHF-tau; in vitro
Disulfide bond
608 – 639
Cross
598 – 598
Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in ubiquitin); alternate
Cross
615 – 615
Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in ubiquitin); alternate
Cross
628 – 628
Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in ubiquitin); in PHF-tau
Cross
634 – 634
Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in ubiquitin); alternate
Cross
638 – 638
Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in ubiquitin); alternate
Alternative sequence
592 – 622
Missing. In isoform Tau-A, isoform Tau-B, isoform Tau-C and isoform Fetal-tau.
Beta strand
618 – 620
Literature citations
Segregation of a missense mutation in the microtubule-associated protein tau gene with familial frontotemporal dementia and parkinsonism.
Dumanchin C.; Camuzat A.; Campion D.; Verpillat P.; Hannequin D.; Dubois B.; Saugier-Veber P.; Martin C.; Penet C.; Charbonnier F.; Agid Y.; Frebourg T.; Brice A.;
Hum. Mol. Genet. 7:1825-1829(1998)
Cited for: VARIANT FTD LEU-618;
Association of missense and 5'-splice-site mutations in tau with the inherited dementia FTDP-17.
Hutton M.; Lendon C.L.; Rizzu P.; Baker M.; Froelich S.; Houlden H.; Pickering-Brown S.; Chakraverty S.; Isaacs A.; Grover A.; Hackett J.; Adamson J.; Lincoln S.; Dickson D.; Davies P.; Petersen R.C.; Stevens M.; de Graaff E.; Wauters E.; van Baren J.; Hillebrand M.; Joosse M.; Kwon J.M.; Nowotny P.; Che L.K.; Norton J.; Morris J.C.; Reed L.A.; Trojanowski J.; Basun H.; Lannfelt L.; Neystat M.; Fahn S.; Dark F.; Tannenberg T.; Dodd P.R.; Hayward N.; Kwok J.B.J.; Schofield P.R.; Andreadis A.; Snowden J.; Craufurd D.; Neary D.; Owen F.; Oostra B.A.; Hardy J.; Goate A.; van Swieten J.; Mann D.; Lynch T.; Heutink P.;
Nature 393:702-705(1998)
Cited for: VARIANTS FTD VAL-589; LEU-618 AND TRP-723;
Pathogenic implications of mutations in the tau gene in pallido-ponto-nigral degeneration and related neurodegenerative disorders linked to chromosome 17.
Clark L.N.; Poorkaj P.; Wszolek Z.; Geschwind D.H.; Nasreddine Z.S.; Miller B.; Li D.; Payami H.; Awert F.; Markopoulou K.; Andreadis A.; D'Souza I.; Lee V.M.-Y.; Reed L.; Trojanowski J.Q.; Zhukareva V.; Bird T.; Schellenberg G.; Wilhelmsen K.C.;
Proc. Natl. Acad. Sci. U.S.A. 95:13103-13107(1998)
Cited for: VARIANTS FTD LYS-596 AND LEU-618;
High prevalence of mutations in the microtubule-associated protein tau in a population study of frontotemporal dementia in the Netherlands.
Rizzu P.; Van Swieten J.C.; Joosse M.; Hasegawa M.; Stevens M.; Tibben A.; Niermeijer M.F.; Hillebrand M.; Ravid R.; Oostra B.A.; Goedert M.; van Duijn C.M.; Heutink P.;
Am. J. Hum. Genet. 64:414-421(1999)
Cited for: VARIANTS FTD VAL-589; LYS-597 DEL; LEU-618 AND TRP-723;
Accelerated filament formation from tau protein with specific FTDP-17 missense mutations.
Nacharaju P.; Lewis J.; Easson C.; Yen S.; Hackett J.; Hutton M.; Yen S.H.;
FEBS Lett. 447:195-199(1999)
Cited for: VARIANTS FTD LEU-618; MET-654 AND TRP-723;
Disclaimer:
Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.